Eric Roberts, MD
Cardiovascular Disease · Milwaukee, WINPI 1407010879
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $103,035 of the $130,756 with a category attached, or 78.8%. 8 manufacturers reported payments, led by United Therapeutics Corporation at 47.1% of the total. Reporting peaked in 2024 at $50,441 and has fallen 77.5% since, to $11,325 in 2025. Among cardiovascular disease clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 163 payments — averaging $802.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$62K
- Actelion Pharmaceuticals US, Inc.$60K
- Merck$8K
- Abbott$621
- Medtronic$239
- Sandoz$186
- plus $251 from 2 others
Across 74 payments — averaging $11,498 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$693K
- Janssen Research & Development, LLC$82K
- Bayer$33K
- United Therapeutics Corporation$23K
- Medtronic$20K
What the payments were for
- Consulting fees$12,44010%
- Speaking & faculty fees$103,03579%
- Travel & lodging$9,1147%
- Food & beverage$5,8324%
- Education$3350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 84 | $61,603 |
| Actelion Pharmaceuticals US, Inc. | 55 | $60,288 |
| Merck | 11 | $7,568 |
| Abbott | 4 | $621 |
| Medtronic | 2 | $239 |
| Sandoz | 4 | $186 |
| Bayer | 2 | $156 |
| Pfizer | 1 | $94 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPSUMIT$59,368
- UPTRAVI$58,608
- REMODULIN$19,137
- TYVASO$8,398
- ORENITRAM$3,417
- WINREVAIR$1,746
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$484
- HeartWare HVAD$239
- Adempas$138
- HeartMate 3 Left Ventricular Dev$137
- TREPROSTINIL$112
How this compares
$130,756 in reported general payments places this provider in the 95th percentile of 322 cardiovascular disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 323 | $7,774,922 |
| Orenitram ErTreprostinil Diolamine | 560 | $7,537,312 |
| AdempasRiociguat | 374 | $4,978,657 |
| OpsumitMacitentan | 341 | $4,340,144 |
| UptraviSelexipag | 140 | $3,293,145 |
| WinrevairSotatercept-Csrk | 74 | $1,108,531 |
| Ambrisentan | 239 | $624,542 |
| Tadalafil | 666 | $334,894 |
| LetairisAmbrisentan | 25 | $313,799 |
| JardianceEmpagliflozin | 293 | $257,935 |
| EntrestoSacubitril/Valsartan | 217 | $190,910 |
| AdcircaTadalafil | 30 | $152,263 |
| EliquisApixaban | 142 | $144,439 |
| XareltoRivaroxaban | 29 | $29,180 |
| Torsemide | 336 | $10,486 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $60,288 | $7,633,289481 claims |
| BayerAdempas | $156 | $4,978,657374 claims |
| MerckWinrevair | $7,568 | $1,108,53174 claims |
| United Therapeutics CorporationAdcirca | $61,603 | $152,26330 claims |
| PfizerEliquis | $94 | $144,439142 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 322 cardiovascular disease providers in Wisconsin.
Other cardiovascular disease in Milwaukee
- Lee BibloMilwaukee$280K
- David GrambowMilwaukee$267K
- Renuka JainMilwaukee$131K
- Evgenia RaichlinMilwaukee$73K
- Prakash ShahMilwaukee$51K
- Sisir SiddamsettiMilwaukee$44K
- Manmeet SinghMilwaukee$39K
- Jordan SwisherMilwaukee$36K
- Christian BreburdaMilwaukee$35K
- Marc AtzenhoeferMilwaukee$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.